The pharma spin-offs have just begun

Want to see more divestment action in Big Pharma? Just wait. That's what investment bankers are predicting, now that Pfizer ($PFE) and AbbVie ($ABBV) have led the way. After all, investors and shareholders responded strongly to Pfizer's animal-health spin-off and nutrition-unit sale--so much so that analysts are calling on CEO Ian Read for more. And AbbVie, the pharma unit spun off by Abbott Laboratories ($ABT) on New Year's Day, has seen its shares climb from a debut at $35 to $45 as of yesterday's close. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.